▲ +8.77% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is $55.80, with a high forecast of $62.00 and a low forecast of $48.00. The average price target represents a 8.77% upside from the last price of $51.30.
The current consensus among 3 contributing investment analysts is to buy stock in OrthoPediatrics. This Buy consensus rating has held steady for over two years.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.